ABNXP Stock Overview
A biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
ABIONYX Pharma SA Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €1.73 |
| 52 Week High | €1.73 |
| 52 Week Low | €1.73 |
| Beta | 0.28 |
| 1 Month Change | 0% |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | 169.36% |
| 5 Year Change | -5.87% |
| Change since IPO | -86.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABNXP | GB Biotechs | GB Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 0.5% |
| 1Y | n/a | -25.8% | 2.7% |
Return vs Industry: Insufficient data to determine how ABNXP performed against the UK Biotechs industry.
Return vs Market: Insufficient data to determine how ABNXP performed against the UK Market.
Price Volatility
| ABNXP volatility | |
|---|---|
| ABNXP Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.0% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in GB Market | 10.5% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: ABNXP has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ABNXP's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2005 | 62 | Cyrille Tupin | abionyx.com |
ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal and ophthalmological diseases. The company is developing CER-001, a negatively-charged lipoprotein particle which contains human recombinant apoA-I, the natural high density lipoprotein (HDL) protein, and sphingomyelin and dipalmitoylphosphatidylglycerol natural phospholipids designed to mimicks the structural and functional biological properties of pre-beta HDL for the treatment of post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients; CER-002, a peroxisome proliferator-activated receptor delta specific agonist for the treatment of cardiovascular and metabolic diseases; and CER-209, a drug candidate for the treatment of metabolic diseases in the liver, as well as atherosclerois and non-alcoholic steato-hepatitis. It has a strategic partnership with GTP Biologics and VBI Therapeutics Group for the bioproduction of the bio-HDL in France.
ABIONYX Pharma SA Fundamentals Summary
| ABNXP fundamental statistics | |
|---|---|
| Market cap | €62.09m |
| Earnings (TTM) | -€5.83m |
| Revenue (TTM) | €3.28m |
18.9x
P/S Ratio-10.7x
P/E RatioIs ABNXP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABNXP income statement (TTM) | |
|---|---|
| Revenue | €3.28m |
| Cost of Revenue | €2.95m |
| Gross Profit | €324.00k |
| Other Expenses | €6.15m |
| Earnings | -€5.83m |
Last Reported Earnings
Jun 30, 2022
Next Earnings Date
Apr 27, 2023
| Earnings per share (EPS) | -0.21 |
| Gross Margin | 9.88% |
| Net Profit Margin | -177.73% |
| Debt/Equity Ratio | 23.6% |
How did ABNXP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/03/28 00:48 |
| End of Day Share Price | 2022/12/30 00:00 |
| Earnings | 2022/06/30 |
| Annual Earnings | 2021/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
ABIONYX Pharma SA is covered by 4 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fanny Meindre | CIC Market Solutions (ESN) |
| Stephanie Lefebvre | Gilbert Dupont |
| Jamila El Bougrini | Gilbert Dupont |